NRx Pharmaceuticals Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval
NRx Pharmaceuticals and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions
NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation
NRx Pharmaceuticals Announces US Food and Drug Administration Receipt of ANDA for KETAFREE, a Preservative-Free IV Ketamine
NRx Pharmaceuticals and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference
HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day Depression Treatment in Partnership with Ampa Health
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director
NRx Pharmaceuticals, Inc. to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference
NRx Pharmaceuticals, Inc. Re-Files Abbreviated New Drug Application for KETAFREE, Preservative-Free IV Ketamine
Tartisan Nickel Corp. Appoints Jack Jacobs, Congressional Medal of Honour Recipient, Retired Army Colonel and Distinguished Business Executive to Board of Advisors
